FILING ANALYSIS · MONDAY, NOVEMBER 9
IONIS PHARMACEUTICALS INC IONS — 8-K: Results of Operations and Financial Condition
neutral
Ionis Pharmaceuticals reported Q3 financial results with total revenue increasing 55% year-over-year, driven by commercial and R&D revenue growth, but lowered 2026 product sales guidance for TRYNGOLZA due to a more gradual than expected launch ramp, while reaffirming total revenue and operating loss guidance
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →